Showing 7921-7930 of 8465 results for "".
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determin
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medi
- ASDS Finds Age Affects Facial Treatment Preferenceshttps://practicaldermatology.com/news/asds-finds-age-affects-facial-treatment-preferences/2458908/A research-based analysis published in Dermatologic Surgery found that facial treatment preferences among women often are tied to their age. Younger women are more likely to seek cosmetic medical treatments for the upper face while women 50 and older prioritize treatments of the lower fa
- Brickell Biotech Appoints Patricia Walker, MD, PhD as President and CSOhttps://practicaldermatology.com/news/brickell-biotech-appoints-patricia-walker-md-phd-as-president-and-cso/2458912/Patricia Walker, MD, PhD has joined Brickell Biotech, Inc. as President and Chief Scientific Officer. Dr. Walker, a board-certified dermatologist specializing in medical and aesthetic dermatology, most recently served as the Chief Medical Officer for Kythera Biopharmaceuticals, Inc. Over
- CMS and AMA Announce Efforts to Ease ICD-10 Transitionhttps://practicaldermatology.com/news/cms-and-ama-announce-efforts-to-ease-icd-10-transition/2458913/The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) are initiating efforts to continue to help physicians get ready ahead of the October 1 deadline to move from ICD-9 to ICD-10 coding for medical diagnoses and inpatient hospital procedures. In respons
- SCOTUS Upholds Affordable Care Act in King v. Burwell Ruling; AADA and AMA Issue Statementshttps://practicaldermatology.com/news/scotus-upholds-affordable-care-act-in-king-v-burwell-ruling-aada-and-ama-issue-statements/2458920/In a 6-3 ruling in King v. Burwell, the US Supreme Court upheld tax subsidies for the Affordable Care Act. Steven J. Stack, MD, President of the American Medical Association release a statement on the decision, saying “The American Medical Association (AMA) is relieved that today&rs
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t